2026-04-27T22:00:53Zhttps://uvadoc.uva.es/oai/request

oai:uvadoc.uva.es:10324/138542025-02-13T09:34:46Zcom_10324_1131com_10324_931com_10324_894col_10324_1201

Bermejo Martín, Jesús Francisco Kelvin, David J. Eiros Bouza, José María Castrodeza Sanz, José Javier Ortiz de Lejarazu Leonardo, Raúl 2015-10-01T08:24:00Z 2015-10-01T08:24:00Z 2009 Journal of Infection Developing Countries 2009; 3(3):159-161. 1972-2680 http://uvadoc.uva.es/handle/10324/13854 10.3855/jidc.18 159 3 161 Journal of Infection in Developing Countries 3 The current outburst of a new H1N1 swine influenza strain(s) in México and the United States is causing great concern in health authorities and in the general population [1]. With the World Health Organization (WHO) reporting the pandemic potential of the new strain, it is necessary to determine which therapeutic options are available until a specific vaccine is available. Based on information from the Centre for Disease Control (CDC), the virus is sensitive to oseltamivir and zanamivir. Antivirals are strongly affected by viral mutations; thus their efficiency could be lost as the virus changes. eng info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-nd/4.0/ Attribution-NonCommercial-NoDerivatives 4.0 International Gripe - Vacunas Macroloides for the treatment of severe respiratory illness caused by novel H1N1 swine influenza viral strains info:eu-repo/semantics/article